Socioeconomic burden of bloodstream infections caused by carbapenem-resistant and carbapenem-susceptible Pseudomonas aeruginosa in China

Clinical and economic burden of community-onset multidrug-resistant infections requiring hospitalization

(2020) I. López-Montesinos et al.   JOURNAL OF INFECTION

A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections

(2019) Qingyi Shi et al.   Antimicrobial Resistance and Infection Control

Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States

(2019) Y.P. Tabak et al.   JOURNAL OF HOSPITAL INFECTION

Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

(2019) Juan P. Horcajada et al.   CLINICAL MICROBIOLOGY REVIEWS

Risk factors for mortality among patients with Pseudomonas aeruginosa bacteremia – retrospective multicenter study

(2019) Tanya Babich et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013

(2018) Alessandro Cassini et al.   Eurosurveillance

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

(2018) Evelina Tacconelli et al.   LANCET INFECTIOUS DISEASES

The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: A propensity score–matched analysis

(2018) Zhihui Chen et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Spencer L James et al.   LANCET

Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections

(2017) Carlos Juan et al.   JOURNAL OF INFECTIOUS DISEASES

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015

(2017) Christopher Troeger et al.   LANCET INFECTIOUS DISEASES

Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients

(2016) William R. Judd et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study

(2016) Alessandro Cassini et al.   PLOS MEDICINE

Disability adjusted life year (DALY): A useful tool for quantitative assessment of environmental pollution

(2015) Tingting Gao et al.   SCIENCE OF THE TOTAL ENVIRONMENT

Imipenem Resistance in Pseudomonas aeruginosa Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes

(2009) Ebbing Lautenbach et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Hospital economic impact of an outbreak of Pseudomonas aeruginosa infections

(2008) R. Bou et al.   JOURNAL OF HOSPITAL INFECTION